Company news: Zelira; ECS Botanics; LGP; Ecofibre; Neurotech; Elixinol; Emyria by Steve Jones and Martin Lane February 28, 2024February 29, 2024 Zelira Therapeutics was hit with a A$30.7m impairment charge in the first half of the financial […]
Quarterly results: Avecho; Melodiol; Bioxyne/BLS; Emyria; Ecofibre; Zelira; Elixinol; AusCann; Botanix by Steve Jones and Martin Lane January 31, 2024February 1, 2024
Financial results: Bioxyne/BLS; Emyria; Ecofibre; Zelira Therapeutics by Martin Lane October 3, 2023October 3, 2023
Financial results: Avecho; Wellnex; Zelira; Emyria; Botanix; MGC Pharma; AusCann; Epsilon; Melodiol; Bioxyne by Martin Lane and Steve Jones September 4, 2023September 4, 2023
Financial results: Bod Science; Zelira Therapeutics; Emyria; Epsilon Healthcare; Elixinol; MGC Pharma by Steve Jones August 1, 2023October 3, 2023
Zelira share price rockets as study shows cannabinoid drug outperforms multibillion dollar Pfizer product by Steve Jones June 1, 2023June 1, 2023
Company news: Zelira Therapeutics; Epsilon Healthcare; Creso Pharma by Martin Lane and Steve Jones May 23, 2023May 23, 2023
Company news: Wellnex Life; Creso Pharma; MGC Pharma; Zelira Therapeutics by Martin Lane March 16, 2023March 16, 2023
Financial results: Elixinol; Emyria; Epsilon; Avecho; Creso Pharma; AusCann; MGC Pharma; Botanix; Zelira by Martin Lane and Steve Jones March 1, 2023March 1, 2023
Company news: Delta 9 Cannabis; Little Green Pharma; Zelira Therapeutics; Emyria by Martin Lane and Steve Jones February 16, 2023February 16, 2023